{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 22 of 129', '4 Schedule of procedures', 'Panel 2 Schedule of trial procedures: screening and treatment periods', 'Treatment period', 'Screening', 'Initial treatment', 'Continuation treatment', 'Details', 'Visit', '1\u00b9', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15', '16', '17', '18', '19', '(protocol section)', 'Week', '-6', '-2', '0', '2', '4', '6', '8', '10', '12', '14', '16', '18', '20', '22', '24', '26', '28', '30', '32', 'Visit window (days\u00b2', '+3', '-3', 'NA', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', 'Trial population and eligibility', 'Informed consent\u00b3', 'X', '8.4, Appendix 3B', 'Eligibility', 'X', '8.1 to 8.4', 'Trial products and randomisation', 'Randomisation', 'X4', '9.2', 'Concomitant medication/procedures', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '9.4,9.5', 'Initiation of emollients (background treatment)', '9.3', 'IMP administration, compliance', 'X6', 'X', 'X', 'X', 'X', 'X', 'X6', 'X6', 'X6', 'X', '9.1.1, 9.1.3.1, 9.2.1, 9.8.3, 9.8.3.1, 9.8.5', 'TCS (NIMP) dispensing', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '9.1.2,9.1.3.2', 'TCS (NIMP) return', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '9.8.3.2, 9.8.5', 'Investigator assessments at baseline', 'C-SSRS', '10.2.1', 'Demographics (age), BSA', '10.2.2. 10.2.5', 'Other demographics and medical history', '10.2.2. 10.2.3', 'Height, weight', '10.2.4', 'Investigator assessment of efficacy', 'IGA, EASI', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '10.3.1.1, 10.3.1.2', 'SCORAD', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '10.3.1.3', 'Atopic dermatitis flares', 'X', 'X', 'X', 'X', 'X', 'X', '10.3.1.4', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 23 of 129', 'Panel 2 Schedule of trial procedures: screening and treatment periods (continued)', 'Treatment period', 'Screening', 'Initial treatment', 'Continuation treatment', 'Details', 'Visit', '1\u00b9', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15', '16', '17', '18', '19', '(protocol section)', 'Week', '-6', '-2', '0', '2', '4', '6', '8', '10', '12', '14', '16', '18', '20', '22', '24', '26', '28', '30', '32', 'Visit window (days2', '+3', '-3', 'NA', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '3', '+3', '3', '+3', '+3', '+3', '+3', '+3', 'Subject assessment of efficacy', 'eDiary training', 'X', '10.3.2', 'eDiary completion', 'POEM', 'X', 'X', 'X', 'X', 'X', 'X', '10.3.2.7', 'DLQI', 'X', 'X', 'X', '10.3.2.8', 'EQ-5D-5L, HADS', '10.3.2.9, 10.3.2.10', 'Safety assessments', 'Vital signs', 'X6', 'X6', 'X6', 'X', 'X', 'X', 'X6', 'X6', 'X6', 'X', 'X', 'X', 'X', 'X', 'X', '10.4.1', 'Physical examination', '10.4.2', 'ECGs', '10.4.3', 'Serum pregnancy test, hepatitis B, C, HIV', '10.4.4, 10.4.5', 'Urine pregnancy test', '10.4.4', 'Serum chemistry, haematology, IgE', '10.4.5', 'Urinalysis', '10.4.5', 'Pharmacokinetics', '10.4.6', 'Anti-drug antibodies', '10.4.7', 'Adverse events', 'X', '11, Appendix 1, Appendix 2', '1)', 'For subjects who do not require a wash-out and subjects who only require washout of topical AD treatment (as specified in the exclusion criteria in Section 8.3), visits 1 and 2', 'will be combined and screening will be reduced to 2 weeks. Hence, these subjects will only attend visit 2 (Week -2) which will include all assessments shown under', 'Week', '-6.', 'The screening period has a maximum duration of 6 weeks.', '2)', 'If', 'the', 'date', 'of a subject visit does not conform to the trial plan, subsequent visits should be planned to maintain the visit schedule relative to randomisation/baseline', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}